<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Challenges in modern medicine</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.52575/2687-0940-2023-46-1-5-15</article-id><article-id pub-id-type="publisher-id">139</article-id><article-categories><subj-group subj-group-type="heading"><subject>INTERNAL DISEASES</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Metabolic Disorders the Post-COVID Period&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Metabolic Disorders the Post-COVID Period&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Panina</surname><given-names>Yulia N.</given-names></name><name xml:lang="en"><surname>Panina</surname><given-names>Yulia N.</given-names></name></name-alternatives><email>doc.panina@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Vishnevskij</surname><given-names>Valery I.</given-names></name><name xml:lang="en"><surname>Vishnevskij</surname><given-names>Valery I.</given-names></name></name-alternatives><email>vishnevsky.orel@mail.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Melchinskaja</surname><given-names>Evgenia N.</given-names></name><name xml:lang="en"><surname>Melchinskaja</surname><given-names>Evgenia N.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Vishnevskij</surname><given-names>Matvei V.</given-names></name><name xml:lang="en"><surname>Vishnevskij</surname><given-names>Matvei V.</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="epub"><year>2023</year></pub-date><volume>46</volume><issue>1</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2023/1/АПМ_2023_5-15_Ch7BqmL.pdf" /><abstract xml:lang="ru"><p>About a fifth of the world&amp;#39;s population suffers from one or more chronic diseases, which exposes them to an increased risk of severe coronavirus infection COVID-19. At the same time, metabolic disorders are often detected, the presence of which plays an important role in the pathogenesis of COVID-19 and is accompanied by a more severe manifestation of the disease. The largest number of hospitalizations and deaths in the world associated with a new coronavirus infection falls on elderly and senile people. Age and concomitant diseases characteristic of the elderly, such as obesity, diabetes mellitus, arterial hypertension, pulmonary, cardiovascular, and renal insufficiency affect the progression and prognosis of COVID-19. Now, more than 2 years after the initial outbreak of SARS-CoV-2, there is strong evidence that people with metabolic diseases are not only more susceptible to severe COVID-19, but also have an increased risk of certain complications. Thus, primary prevention remains the best strategy to avoid post-COVID syndrome and associated metabolic disorders.</p></abstract><trans-abstract xml:lang="en"><p>About a fifth of the world&amp;#39;s population suffers from one or more chronic diseases, which exposes them to an increased risk of severe coronavirus infection COVID-19. At the same time, metabolic disorders are often detected, the presence of which plays an important role in the pathogenesis of COVID-19 and is accompanied by a more severe manifestation of the disease. The largest number of hospitalizations and deaths in the world associated with a new coronavirus infection falls on elderly and senile people. Age and concomitant diseases characteristic of the elderly, such as obesity, diabetes mellitus, arterial hypertension, pulmonary, cardiovascular, and renal insufficiency affect the progression and prognosis of COVID-19. Now, more than 2 years after the initial outbreak of SARS-CoV-2, there is strong evidence that people with metabolic diseases are not only more susceptible to severe COVID-19, but also have an increased risk of certain complications. Thus, primary prevention remains the best strategy to avoid post-COVID syndrome and associated metabolic disorders.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>postCOVID syndrome</kwd><kwd>long COVID</kwd><kwd>metabolic disorders</kwd><kwd>hyperglycemia</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>postCOVID syndrome</kwd><kwd>long COVID</kwd><kwd>metabolic disorders</kwd><kwd>hyperglycemia</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Belocerkovckaya Yu.G., Romanovckix A.G., Cmirnov I.P., Cinopal`nikov A.I. 2021. Dolgij COVID-19 [Long COVID-19]. Consilium Medicum. 23 (3): 261&amp;ndash;268. doi: 10.26442/20751753.2021.3.200805</mixed-citation></ref><ref id="B2"><mixed-citation>Bondarev C.A., Achkacov E.E., Cmirnov V.V., Shishkin A.N., Xudyakova N.V., Ry`bka T.G. 2020. Vliyanie arterial`noj gipertenzii i drugix faktorov ricka na razvitie fibrillyacii predcerdij u cportcmenov [Hypertension and other risk factors of atrial fibrillation in athletes]. Arterial`naya gipertenziya. 26 (4): 362&amp;ndash;370. doi: 10.18705/1607-419X-2020-26-4-362-370</mixed-citation></ref><ref id="B3"><mixed-citation>Kogan E.A., Berezovckij Yu.C., Procenko D.D., Bagdacaryan T.R., Greczov E.M., Demura C.A., Demyashkin G.A., Kalinin D.V., Kukleva A.D., Kurilina E.V., Nekracova T.P., Paramonova N.B., Ponomarev A.B., Radencka-Lopovok C.G., Cemenova L.A., Terty`chny`j A.C. 2020. Patologicheckaya anatomiya infekcii, vy`zvannoj SARS-CoV-2 [Pathological Anatomy of Infection Caused by SARS-CoV-2]. Cudebnaya medicina. 6 (2): 8&amp;ndash;30. doi: 10.19048/2411-8729-2020-6-2-8-30</mixed-citation></ref><ref id="B4"><mixed-citation>Ojnotkinova O.Sh., Maclennikova O.M., Larina V.N., Rzhevckaya E.V., Cy`rov A.V., Dedov E.I., Kryukov E.V., Ecin E.V., Zhuravleva M.V., Voevoda M.I., Demidova T.Yu., Achkacov E.E., Cpacckij A.A., Shaxnovich P.G. 2020. Coglacovannaya e`kcpertnaya poziciya po diagnoctike i lecheniyu ful`minantnogo miokardita v ucloviyax pandemii COVID-19 [Expert consensus statement on the diagnosis and treatment of fulminant myocarditis in the context of the COVID-19 pandemic]. Akademiya mediciny` i cporta. 1 (2): 28&amp;ndash;40. doi: 10.15829/2712-7567-2020-2-13</mixed-citation></ref><ref id="B5"><mixed-citation>Orlov Yu.P., Govorova N.V., Korpacheva O.V., Afanac`ev V.V., Xilenko I.A. 2021. O vozmozhnocti icpol`zovaniya preparatov gruppy` cukcinatov v ucloviyax gipokcii pri COVID-19 [On the Possibility of Using Succinate in Hypoxia Developing in COVID-19]. Obshhaya reanimatologiya. 17 (3): 78&amp;ndash;98. doi: 10.15360/1813-9779-2021-3-78-98</mixed-citation></ref><ref id="B6"><mixed-citation>Ucacheva E.V. 2016. Mify` i real`noct` kardioprotektivnoj terapii [Myths and reality of cardioprotective therapy]. 24 (9): 546&amp;ndash;550.</mixed-citation></ref><ref id="B7"><mixed-citation>Acuti Martellucci C., Flacco M.E., Cappadona R., Bravi F., Mantovani L., Manzoli L. 2020. SARS-CoV-2 pandemic: An. overview. Adv. Biol. Regul. 77: 100736. doi: 10.1016/j.jbior.2020.100736</mixed-citation></ref><ref id="B8"><mixed-citation>Adhikari S.P., Meng S., Wu Y.J., Mao Y.P., Ye R.X., Wang Q.Z., Sun C., Sylvia S., Rozelle S., Raat H., Zhou H. 2020. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect. Dis. Poverty. 9 (1): 29. doi: 10.1186/s40249-020-00646-x</mixed-citation></ref><ref id="B9"><mixed-citation>Alfano G., Fontana F., Mori G., Giaroni F., Ferrari A., Giovanella S., Ligabue G., Ascione E., Cazzato S., Ballestri M., Di Gaetano M., Meschiari M., Menozzi M., Milic J., Andrea B., Franceschini E., Cuomo G., Magistroni R., Mussini C., Cappelli G., Guaraldi G. 2022. Modena COVID-19 Working Group (MoCo19). Acid base disorders in patients with COVID-19. Int. Urol. Nephrol. 54&amp;nbsp;(2): 405&amp;ndash;410. doi: 10.1007/s11255-021-02855-1</mixed-citation></ref><ref id="B10"><mixed-citation>Avanzato V.A., Matson M.J., Seifert S.N., Pryce R., Williamson B.N., Anzick S.L., Barbian K., Judson&amp;nbsp;S.D., Fischer E.R., Martens C., Bowden T.A., de Wit E., Riedo F.X., Munster V.J. 2020. Case study: Prolonged infectious SARSCoV-2 shedding from an asymptomatic immunocompromised cancer patient. Cell. 183 (7): 1901&amp;ndash;1912. doi: 10.1016/j.cell.2020.10.049</mixed-citation></ref><ref id="B11"><mixed-citation>Bezuidenhout M.C., Wiese O.J., Moodley D., Maasdorp E., Davids M.R., Koegelenberg C.F., Lalla U., Khine-Wamono A.A., Zemlin A.E., Allwood B.W. 2021. Correlating arterial blood gas, acid-base and blood pressure abnormalities with outcomes in COVID-19 intensive care patients. Ann. Clin. Biochem. 58 (2): 95&amp;ndash;101. doi: 10.1177/0004563220972539</mixed-citation></ref><ref id="B12"><mixed-citation>Cariou B., Pichelin M., Goronflot T., Gonfroy C., Marre M., Raffaitin-Cardin C., Thivolet C., Wargny&amp;nbsp;M., Hadjadj S., Gourdy P. 2021. CORONADO investigators. Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO study. Diabetes Res. Clin. Pract.175. doi: 10.1016/j.diabres.2021.108695</mixed-citation></ref><ref id="B13"><mixed-citation>Carrasco-S&amp;aacute;nchez F.J., L&amp;oacute;pez-Carmona M.D., Mart&amp;iacute;nez-Marcos F.J., P&amp;eacute;rez-Belmonte L.M., Hidalgo-Jim&amp;eacute;nez A., Buonaiuto V., Su&amp;aacute;rez Fern&amp;aacute;ndez C., Freire Castro S.J., Luordo D., Pesqueira Fontan&amp;nbsp;P.M., Bl&amp;aacute;zquez Encinar J.C., Magallanes Gamboa J.O., de la Pe&amp;ntilde;a Fern&amp;aacute;ndez A., Torres&amp;nbsp;Pe&amp;ntilde;a J.D., Fern&amp;aacute;ndez Sol&amp;agrave; J., Napal Lecumberri J.J., Amor&amp;oacute;s Mart&amp;iacute;nez F., Guisado Espartero M.E., Jorge Ripper C., G&amp;oacute;mez M&amp;eacute;ndez R., Vicente L&amp;oacute;pez N., Rom&amp;aacute;n Bernal B., Rojano Rivero M.G., Ramos Rinc&amp;oacute;n J.M., G&amp;oacute;mez Huelgas R. 2021. SEMI-COVID-19 Network. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry. Ann. Med. 53 (1): 103&amp;ndash;116. doi: 10.1080/07853890.2020.1836566</mixed-citation></ref><ref id="B14"><mixed-citation>Casta&amp;ntilde;eda S., Remuzgo-Mart&amp;iacute;nez S., L&amp;oacute;pez-Mej&amp;iacute;as R., Genre F., Calvo-Al&amp;eacute;n J., Llorente I., Aurrecoechea E., Ortiz A.M., Triguero A., Blanco R., Llorca J., Gonz&amp;aacute;lez-Gay M.A. 2019. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol. 37: 465&amp;ndash;473.</mixed-citation></ref><ref id="B15"><mixed-citation>De Leo S., Lee S.Y., Braverman L.E. Hyperthyroidism. Lancet 2016; 388: 906&amp;ndash;918. doi: 10.1016/S0140-6736(16)00278-6</mixed-citation></ref><ref id="B16"><mixed-citation>Group R.C. 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 397: 1637&amp;ndash;1645. doi: 10.1016/S0140-6736(21)00676-0</mixed-citation></ref><ref id="B17"><mixed-citation>Guerstein S., Romeo-Aznar V., Dekel M., Miron O., Davidovitch N., Puzis R., Pilosof S. 2021. The interplay between vaccination and social distancing strategies affects COVID19 population-level outcomes. PLoS Comput Biol. 17 (8): e1009319. doi: 10.1371/journal.pcbi.1009319</mixed-citation></ref><ref id="B18"><mixed-citation>Inaba H., Aizawa T. 2021. Coronavirus Disease 2019 and the Thyroid &amp;ndash; Progress and Perspectives. Front Endocrinol (Lausanne). 12: 708333. doi: 10.3389/fendo.2021.708333</mixed-citation></ref><ref id="B19"><mixed-citation>Kosiborod M.N., Esterline R., Furtado R.H.M., Oscarsson J., Gasparyan S.B., Koch G.G., Martinez F., Mukhtar O., Verma S., Chopra V., Buenconsejo J., Langkilde A.M., Ambery P., Tang F., Gosch&amp;nbsp;K., Windsor S.L., Akin E.E., Soares R.V.P., Moia D.D.F., Aboudara M., Hoffmann Filho&amp;nbsp;C.R., Feitosa A.D.M., Fonseca A., Garla V., Gordon R.A., Javaheri A., Jaeger C.P., Leaes&amp;nbsp;P.E., Nassif M., Pursley M., Silveira F.S., Barroso W.K.S., Lazcano Soto J.R., Nigro Maia&amp;nbsp;L., Berwanger O. 2021. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 9: 586&amp;ndash;594. doi: 10.1016/S2213-8587(21)00180-7</mixed-citation></ref><ref id="B20"><mixed-citation>Kudose S., Batal I., Santoriello D., Xu K., Barasch J., Peleg Y., Canetta P., Ratner L.E., Marasa M., Gharavi A.G., Stokes M.B., Markowitz G.S, D&amp;#39;Agati V.D. 2020. Kidney biopsy findings in patients with COVID-19. Journal of the American Society of Nephrology. 9 (31): 1959&amp;ndash;1968. doi: 10.1681/ASN.2020060802</mixed-citation></ref><ref id="B21"><mixed-citation>Mallah S.I., Ghorab O.K., Al-Salm S., Abdellatif O.S., Tharmaratnam T., Iskandar M A., Sefen, J.A.N., Sidhu P., Atallah B., El-Lababid, R., Al-Qahtan M. 2021. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 201: 35. doi: 10.1186/s12941-021-00438-7</mixed-citation></ref><ref id="B22"><mixed-citation>Marfella R., Paolisso P., Sardu C., Bergamaschi L., D&amp;#39;Angelo E.C., Barbieri M., Rizzo M.R., Messina V., Maggi P., Coppola N., Pizzi C., Biffi M., Viale P., Gali&amp;eacute; N., Paolisso G. 2020. Negative impact of hyperglycaemia on tocilizumab therapy in COVID-19 patients. Diabetes Metab. 46: 403&amp;ndash;405. doi: 10.1016/j.diabet.2020.05.005</mixed-citation></ref><ref id="B23"><mixed-citation>Mazori A.Y., Bass I.R., Chan L., Mathews K.S., Altman D.R., Saha A., Soh H., Wen H.H., Bose S., Leven E., Wang J.G., Mosoyan G., Pattharanitima P., Greco G., Gallagher E.J. 2021. Hyperglycemia is associated with increased mortality in critically ill patients with COVID-19. Endocr Pract. 27 (2): 95&amp;ndash;100. doi: 10.1016/j.eprac.2020.12.015</mixed-citation></ref><ref id="B24"><mixed-citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O&amp;#39;Hara M., Suett J., Dahmash&amp;nbsp;D., Bugaeva P., Rigby I., Munblit D., Harriss E., Burls A., Foote C., Scott J., Carson G., Olliaro P., Sigfrid L., Stavropoulou C. 2021. Characterising long COVID: a living systematic review. BMJ Global Health. 6: e005427. doi: 10.1136/bmjgh-2021-005427</mixed-citation></ref><ref id="B25"><mixed-citation>National Center for Biotechnology Information. 2022. PubChem Compound Summary for CID 10917, Levocarnitine. 2022; from https://pubchem.ncbi.nlm.nih.gov/compound/Levocarnitine.</mixed-citation></ref><ref id="B26"><mixed-citation>Noh Y., Oh I.S., Jeong H.E., Filion K.B., Yu O.H.Y., Shin J.Y. 2021. Association between DPP-4 inhibitors and COVID-19-related outcomes among patients with type 2 diabetes. Diabetes Care. 44: e64&amp;ndash;e66. doi: 10.2337/dc20-1824</mixed-citation></ref><ref id="B27"><mixed-citation>Post-COVID Conditions. CDC, 2021, Updated July 12. 2021. [https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html].</mixed-citation></ref><ref id="B28"><mixed-citation>Raman B., Bluemke D.A., L&amp;uuml;scher T.F., Neubauer S. 2022. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 43: 1157&amp;ndash;1172. doi: 10.1093/eurheartj/ehac031</mixed-citation></ref><ref id="B29"><mixed-citation>Santos A., Magro D.O, Evangelista-Poderoso R., Saad M.J.A. 2021. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr.13: 23. doi: 10.1186/s13098-021-00639-2</mixed-citation></ref><ref id="B30"><mixed-citation>Scappaticcio L., Pitoia F., Esposito K., Piccardo A., Trimboli P. 2021. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord. 22 (4): 803-815. doi: 10.1007/s11154-020-09615-z</mixed-citation></ref><ref id="B31"><mixed-citation>Seeherman S., Suzuki Y.J. 2021. Viral Infection and Cardiovascular Disease: Implications for the Molecular Basis of COVID-19 Pathogenesis. Int. J. Mol. Sci. 22 (4): 1659. doi: 10.3390/ijms22041659</mixed-citation></ref><ref id="B32"><mixed-citation>Solerte S.B., D&amp;#39;Addio F., Trevisan R., Lovati E., Rossi A., Pastore I., Dell&amp;#39;Acqua M., Ippolito E., Scaranna C., Bellante R., Galliani S., Dodesini A.R., Lepore G., Geni F., Fiorina R.M., Catena E., Corsico A., Colombo R., Mirani M., De Riva C., Oleandri S.E., Abdi R., Bonventre J.V., Rusconi&amp;nbsp;S., Folli F., Di Sabatino A., Zuccotti G., Galli M., Fiorina P. 2020. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care. 43: 2999&amp;ndash;3006. doi: 10.2337/dc20-1521</mixed-citation></ref><ref id="B33"><mixed-citation>Velavan T.P., Kieu Linh L.T., Kreidenweiss A., Gabor J., Krishna S., Kremsner P.G. 2021. Longitudinal monitoring of lactate in hospitalized and ambulatory COVID-19 patients. Am. J. Trop. Med. Hyg. 104 (3): 1041&amp;ndash;1044. doi: 10.4269/ajtmh.20-1282</mixed-citation></ref><ref id="B34"><mixed-citation>Zhou H., Yang J., Zhou C., Chen B., Fang H., Chen S., Zhang X., Wang L., Zhang L. 2021. A Review of SARS-CoV2: compared With SARS-CoV and MERS-CoV. Front Med (Lausanne). 8:628370. doi: 10.3389/fmed.2021.628370</mixed-citation></ref></ref-list></back></article>